Edgewise Therapeutics (EWTX) vs PTC Therapeutics (PTCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed PTC Therapeutics (PTCT) over the past year, gaining 76.0% versus a loss of 28.1%. Over five years, EWTX leads with a +95.8% price change compared with +48.2% for PTCT. PTC Therapeutics is the larger company by market cap ($4.71 billion vs $4.37 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | PTCT |
|---|---|---|
| Share price | $39.91 | $56.42 |
| Market cap | $4.37B | $4.71B |
| 1-day change | -3.07% | -3.27% |
| YTD return | +60.81% | -25.72% |
| 1-year return | +76.03% | -28.10% |
| 5-year return | +95.80% | +48.24% |
| P/E ratio (TTM) | 4.76 | — |
| Forward P/E | — | 17.69 |
| EPS (TTM) | $8.38 | $-1.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.73B |
| Revenue growth (YoY) | — | +114.51% |
| Net income (latest FY) | $-167.79M | $682.64M |
| Operating margin | — | 50.09% |
| Net margin | — | 39.44% |
| 52-week high | $48.78 | $90.87 |
| 52-week low | $19.76 | $56.18 |
| Distance from 52-week high | -18.19% | -37.91% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +38.88% | +78.08% |
| Average volume | 1.53M | 1.07M |
| Shares outstanding | 109.48M | 83.54M |
| Employees | 133 | 991 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed PTCT by 104.1 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Health Care · Biotechnology: Pharmaceutical Preparations · 133 employees
About PTC Therapeutics
PTCT stock →PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 991 employees
EWTX vs PTCT FAQ
Which is bigger, Edgewise Therapeutics or PTC Therapeutics?
PTC Therapeutics (PTCT) is larger, with a market capitalization of $4.71B compared with $4.37B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, EWTX or PTCT?
EWTX returned +76.03% over the past 12 months, compared with -28.10% for PTCT (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and PTC Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.